AstraZeneca just signed off on a $34 million check to make a Texas Medicaid fraud case disappear, and the underlying complaint reads like a playbook other drugmakers should already recognize.
The $34 million settlement resolves claims under Texas Human Resources Code Chapter 36, the state’s Health Care Program Fraud Prevention Act. Texas alleged AZ supplied free nursing services and reimbursement support to prescribers “under the guise of non-branded counseling,” steering Medicaid-covered prescriptions toward its own drugs. Texas said the result was millions of dollars in tainted Medicaid claims. AZ didn’t admit wrongdoing; the agreement cites only a “mutual desire to settle… amicably.”
I’ve read enough consent agreements to know that line is boilerplate. The real story is the pattern: Attorney General Ken Paxton has now run this same free-nurse theory against three companies within a year. He sued Eli Lilly over similar free-nurse allegations, then filed a similar case against Sanofi. AstraZeneca folded first. That settlement number becomes the benchmark plaintiffs’ counsel will cite against the other two.
Lilly faced nursing-service allegations over insulin marketing a decade ago, Novo Nordisk a “white coat” sales scheme. What’s changed is the venue: a state AG running Chapter 36 unlawful-inducement claims instead of waiting on the federal Anti-Kickback Statute.
Worth auditing your own field reimbursement support contracts this quarter, especially anything labeled “non-branded.”
— Rebecca Lauren